Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of CT-707 versus crizotinib in ALK-positive advanced non-small cell lung cancer
CTR20200770Phase 3Completed
- Sponsor
- Beijing Sailintai Pharmaceutical Technology
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of conteltinib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Sailintai Pharmaceutical Technology. Started Aug 2020; status: completed.
02
Drugs
conteltinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200770.